Supplementary Data Figure S2 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
Year: 2023
Type: supplementary-materials
Abstract: ARX788 activity in HER2-transduced MDA-MB-435 pools. MDA-MB-435 cells transduced with HER2 were sorted into pools with low, medium, and high HER2 expression and quantified for HER2 expression by QiFiKit analysis. Parental MDA-MB-435 cells and the pools were treated with ARX788 for 3 days at 37{degree sign}C, and cell viability was measured.
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362489757